05:21:16 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2022-01-26 Bokslutskommuniké 2021
2021-07-14 Kvartalsrapport 2021-Q2
2021-06-30 Årsstämma 2021
2021-05-27 Ordinarie utdelning NATTO 0.00 NOK
2021-02-17 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-07-15 Kvartalsrapport 2020-Q2
2020-06-22 Ordinarie utdelning NATTO 0.00 NOK
2020-06-19 Årsstämma 2020
2020-05-06 Kvartalsrapport 2020-Q1
2020-02-19 Bokslutskommuniké 2019
2019-11-13 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-31 Ordinarie utdelning NATTO 0.00 NOK
2019-05-29 Årsstämma 2019
2019-04-30 Kvartalsrapport 2019-Q1
2019-02-13 Bokslutskommuniké 2018
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning NATTO 0.00 NOK
2018-05-30 Årsstämma 2018
2018-02-08 Bokslutskommuniké 2017
2017-11-24 Extra Bolagsstämma 2017
2017-08-16 Kvartalsrapport 2017-Q2
2017-05-16 Ordinarie utdelning NATTO 0.00 NOK
2017-05-15 Kvartalsrapport 2017-Q1
2017-05-15 Kapitalmarknadsdag 2017
2017-05-15 Årsstämma 2017
2017-02-08 Bokslutskommuniké 2016
2016-11-16 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-20 Kvartalsrapport 2016-Q1
2016-05-20 Årsstämma 2016
2016-02-26 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2014-11-26 Kvartalsrapport 2014-Q3
2014-08-27 Kvartalsrapport 2014-Q2
2014-05-27 Kvartalsrapport 2014-Q1
2014-02-17 Bokslutskommuniké 2013
2013-11-26 Kvartalsrapport 2013-Q3
2013-08-27 Kvartalsrapport 2013-Q2
2013-05-22 Kvartalsrapport 2013-Q1
2013-02-28 Bokslutskommuniké 2012
2012-11-15 Kvartalsrapport 2012-Q3
2012-08-21 Kvartalsrapport 2012-Q2
2012-05-16 Kvartalsrapport 2012-Q1
2012-02-28 Bokslutskommuniké 2011
2012-02-13 Extra Bolagsstämma 2012
2011-11-17 Kvartalsrapport 2011-Q3
2011-10-31 Extra Bolagsstämma 2011
2011-08-18 Kvartalsrapport 2011-Q2
2011-05-19 Kvartalsrapport 2011-Q1
2011-02-25 Bokslutskommuniké 2010

Beskrivning

LandNorge
ListaOAX Equities
SektorHälsovård
IndustriLäkemedel & Handel
NattoPharma är ett norskt bolag verksamma inom utveckling av läkemedel. Idag innehas störst fokus på utveckling av diverse kosttillskott. Ledande varumärken säljs huvudsakligen via MenaQ7, ett vitamintillskott av K2 karaktär. En stor del av verksamheten fokuserar på forskning och utveckling inom arbetsområdet, vilket sker via separata dotterbolag. Bolaget etablerades 2004 och har sitt huvudkontor i Oslo.
2021-03-01 22:34:59
Reference is made to the mandatory notification of trade in NattoPharma ASA
("NattoPharma") by primary insiders today at 9:05 AM. TG Montgomery AS ("TGM"),
as a related party to NattoPharma's chairman of the Board, Frode Marc Bohan, and
deputy board member, Kim Øien, have agreed to purchase additional 56,000 shares
in NattoPharma at a price of NOK 38 per share, subject to the voluntarily offer
(the "Offer") that Compagnie des Levures Lesaffre ("Lesaffre") is due to launch
with an offer period that will commence on or prior to 19 March 2021 being
completed, cf. the press release dated 15 February 2021 regarding the Offer and
NattoPharma's stock exchange notice dated 25 February 2021 regarding amendments
to the Offer.

TGM's pre-acceptance of the Offer covers any shares TGM owned the date TGM gave
its irrevocable pre-acceptance to Lesaffre and any shares that TGM may acquire
in NattoPharma prior to the completion of the Offer. This means that TGM upon
completion of the acquisition of the 56,000 shares covered by this notice and
the 330,360 shares reported earlier today (collectively the "Additional Shares")
will transfer the Additional Shares to Lesaffre for the offer price, which
currently is NOK 35.

Following the completion of the acquisition of the Additional Shares, TGM will
hold 2,121,482 shares in NattoPharma, representing 10.69% of the
total registered share capital and voting rights in NattoPharma, while primary
insider Frode Bohan together with TGM and other related parties will control
4,032,789 shares in NattoPharma representing 20.32% of the total registered
share capital and voting rights in NattoPharma, excluding 100,000 options
NattoPharma that Frode Bohan has agreed to exercise and transfer to Lesaffre
under the Offer.

Following the completion of the acquisition of the Additional Shares, primary
insider Kim Øien together with TGM and other related parties will control
2,321,482 shares in NattoPharma  representing 11.70% of the total registered
share capital and voting rights in NattoPharma.